Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on June 30th, 2014% (San José Library/Flicker)
30 June 2014. Researchers at University of California in San Francisco and Kennedy Krieger Institute in Baltimore completed a clinical trial conducted entirely online testing the ability of omega-3 fatty acids to control hyperactivity in children with autism. The team led by UC-San Francisco medical professor Stephen Bent published its findings . . . → Read More: Online Clinical Trial with Children Tests Autism Therapy
By Alan, on June 30th, 2014% (Genome.gov)
30 June 2014. PierianDx, a new company formed by medical faculty and practitioners at Washington University in St. Louis, licensed genomic technology from the university to commercialize diagnostic tools for personalized medicine. Financial details of the licensing deal were not disclosed.
The start-up company plans to offer the technology in a system . . . → Read More: Spin-Off Licenses Genomic Technology from Wash. University
By Alan, on June 27th, 2014% (Investor.gov)
27 June 2014. Researchers from the insurance provider Aetna Inc. and GNS Healthcare, a data analytics company in the health care industry, developed statistical models that can identify population groups and individuals at risk for metabolic syndrome, a collection of conditions pointing to future heart disorders and diabetes. The team from Aetna’s . . . → Read More: Big Data Analytics ID People Risking Metabolic Syndrome
By Alan, on June 27th, 2014% ReWalk system (Argo Medical Technologies Inc.)
27 June 2014. The Food and Drug Administration yesterday cleared for sale in the U.S. a motorized exoskeleton system for people with lower-body paralysis from spinal cord injury. The device, called ReWalk, is made by Argo Medical Technologies in Marlborough, Massachusetts, and according to FDA, the first . . . → Read More: FDA Approves Motorized Exoskeleton for Spinal Cord Injury
By Alan, on June 26th, 2014% (National Institute on Aging, NIH)
26 June 2014. A late-stage clinical trial testing a topical gel to treat diabetic nerve pain completed its enrollment, according to BioDelivery Sciences International in Raleigh, North Carolina, the study’s sponsor. The trial is the first of two clinical studies of Clonidine Topical Gel in preparation for the . . . → Read More: Late Trial Testing Topical Gel for Diabetic Nerve Pain
By Alan, on June 26th, 2014% Jennifer Lewis (Harvard University)
26 June 2014. Engineers at Harvard University developed an ink made of epoxy resins and carbon fibers, which when arrayed into a cellular pattern with three-dimensional printing, can produce a strong lightweight composite with the properties of balsa wood. Materials scientist and engineering professor Jennifer Lewis and postdoctoral researcher Brett . . . → Read More: Epoxy/Carbon Ink 3-D Printed into Lightweight Cell Material
By Alan, on June 25th, 2014% (HealthIT.gov)
25 June 2014. The Kaiser Permanente health plan in Southern California, headquartered in Pasadena, established a follow-up monitoring system for plan members visiting doctors’ offices or outpatient clinics that scans its electronic health records database for gaps in outpatient care. A team from Kaiser Permanente’s Southern California network, led by regional quality . . . → Read More: Outpatient Safety Net Harnesses Electronic Health Data
By Alan, on June 25th, 2014% 3-D brain wiring illustration (NIH)
25 June 2014. An early-stage clinical trial by Neuralstem Inc. in Germantown, Maryland provides evidence its experimental drug to treat major depressive disorder is having a positive impact on patients’ brain activity and behavior. The company reported the findings yesterday at a meeting of the International College of . . . → Read More: Early Trial Shows Neural Regrowth Effects on Depression
By Alan, on June 24th, 2014% Neurobridge stimulation sleeve on Ian Burkhart’s arm (Ohio State University)
24 June 2014. Engineers at Battelle Memorial Institute and physicians at Ohio State University medical center in Columbus demonstrated a device that enables people with a spinal cord injury to direct movement of limbs with their thoughts. The research team’s first patient is . . . → Read More: Paralyzed Man Moves Hand with Neuro-Signal Implant System
By Alan, on June 24th, 2014% David Mooney (Harvard University)
24 June 2014. Bioengineers at Harvard University developed a technique with hydrogel and ultrasound that makes it possible to trigger short-term on-demand boosts of chemotherapy drugs. The team led by David Mooney of Harvard’s Wyss Institute for Biologically Inspired Engineering published its findings online today in the Proceedings of the . . . → Read More: Ultrasound-Triggered Hydrogel Shown to Deliver Cancer Drug
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|
You must be logged in to post a comment.